

Distinct Patterns of DNA Copy Number Alterations Associate with *BRAF* Mutations in Melanomas and Melanoma-Derived Cell Lines

J. Greshock,¹ K. Nathanson,² A. Medina,² M. R. Ward,² M. Herlyn,³ B. L. Weber,¹ and T. Z. Zaks^{1*}

¹Translational Medicine Oncology, GlaxoSmithKline, King of Prussia, PA

²Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA

³The Wistar Institute, Philadelphia, PA

A majority of malignant melanomas harbor an oncogenic mutation in either *BRAF* or *NRAS*. If *BRAF* and *NRAS* transform melanoma cells by a similar mechanism, then additional genetic aberrations would be similar (or random). Alternatively, distinct mutation-associated changes would suggest the existence of unique cooperating requirements for each mutation group. We first analyzed a panel of 52 melanoma cell lines ($n = 35, 11, 6$ for *BRAF*^{*}, *NRAS*^{*}, and *BRAF/NRAS*^{w^t/w^t}, respectively) by array-based comparative genomic hybridization for unique alterations that associate with each mutation subgroup. Subsequently, those DNA copy number changes that correlated with a mutation subgroup were used to predict the mutation status of an independent panel of 43 tumors ($n = 17, 13, 13$ for *BRAF*^{*}, *NRAS*^{*}, and *BRAF/NRAS*^{w^t/w^t}, respectively). *BRAF* mutant tumors were classified with a high rate of success (74.4%, $P = 0.002$), whereas *NRAS* mutants were not significantly distinguished from wild types (26/43, $P = 0.12$). Copy number gains of 7q32.1-36.3, 5p15.31, 8q21.11, and 8q24.11 were most strongly associated with *BRAF*^{*} tumors and cell lines, as were losses of 11q24.2-24.3. *BRAF*^{*} melanomas appear to be associated with a specific profile of DNA copy number aberrations that is distinct from those found in *NRAS*^{*} and *BRAF/NRAS*^{w^t/w^t} tumors. These findings suggest that although both *BRAF* and *NRAS* appear to function along the same signal transduction pathway, each may have different requirements for cooperating oncogenic events. The genetic loci that make up this profile may harbor therapeutic targets specific for tumors with *BRAF* mutations. © 2009 Wiley-Liss, Inc.

INTRODUCTION

Melanoma, a neural-crest derived cancer, has few effective therapies that curtail its progression upon metastasis. The pathology of these heterogeneous cancers are often broadly defined by whether they are sun-induced or not by their location (e.g., sun-exposed skin versus mucosal) (reviewed in Chudnovsky et al., 2005). Current research efforts have focused on genetic and genomic alterations associated with these pathological groupings (reviewed in Kabbarah and Chin, 2005). The most common oncogenic event in melanoma is the activation of the MAPK pathway, normally caused by mutations of the *BRAF* or *NRAS* genes (Davies et al., 2002). This has been shown to increase tumor proliferation and survival (Hoefflich et al., 2006) as well as facilitate the transition to a malignancy in the stage IV vertical growth phase (Hingorani et al., 2003). The *NRAS* locus, although less frequently mutated in primary melanomas (Poynter et al., 2006), has been similarly shown to suppress apoptosis in knockdown experiments (Eskandarpour et al., 2005).

Early accounts of *BRAF* mutations in melanomas estimated their occurrence in ~50% of all metastatic tumors, and this frequency may be even higher in benign nevi (Uribe et al., 2003; Poynter et al., 2006) and in certain melanoma subtypes (Poynter et al., 2006). For example, non-sun-induced and mucosal melanomas appear to have a lower mutation rate of *BRAF* than those originating in regions of intermittent sun exposure on the dermis (Maldonado et al., 2003) where mutated *KIT* may be a dominant oncogene (Curtin et al., 2006). Mutations of *NRAS* are considerably less common, and estimates of the frequency vary between ~6 (Poynter et al., 2006) and ~25% of primary sporadic melanomas (Omholt et al.,

Additional Supporting Information may be found in the online version of this article.

Supported by: National Cancer Institute Melanoma Specialized Program of Research Excellence (SPORE), Grant number: P50 CA093372.

*Correspondence to: T. Z. Zaks, Clinical Research Oncology, Cephalon, Inc, Frazer, PA, USA. E-mail: tzaks@cephalon.com

Received 13 October 2008; Accepted 22 January 2009

DOI 10.1002/gcc.20651

Published online 18 February 2009 in Wiley InterScience (www.interscience.wiley.com).

2003). Their differential occurrence in histological subtypes of melanoma is not as clear.

DNA copy number instability has been coupled with the deregulation of several key oncogenic pathways. For example, specific alterations appear to associate with somatic transformation of the *RB* pathway in breast cancers (Fridlyand et al., 2006). Further, particular sets of copy number alterations have been shown to be directly related to distinct expression profiles associated with breast cancer clinical subtypes (Bergamaschi et al., 2006). At the transcript level, Pavey et al. (2004) successfully classified sporadic malignant melanoma cell lines based upon activating *BRAF* mutations. Although not yet described in melanomas, unique *NRAS** expression profiles have been noted in thyroid papillary carcinomas (Giordano et al., 2005) as well as in acute myeloid leukemias (Neben et al., 2005). Previously studies of DNA copy number alterations in melanoma have indirectly demonstrated unique gains and losses associated with sporadic cases (where mutations of *BRAF* are most prevalent) when compared with those subject to chronic sun damage and nondermal tumors (Curtin et al., 2005). Further, melanoma-derived cell lines broadly cluster by alterations associated with *BRAF/NRAS* mutations (Jonsson et al., 2007; Lin et al., 2008). However, the relationship to *BRAF* and/or *NRAS* mutations in these subgroups has not been investigated in primary tumors.

If *BRAF* mutations are an early event in oncogenesis of melanoma, then tumors harboring a mutant *BRAF* would subsequently develop additional nonrandom cancer-promoting alterations, which may include cooperating alterations. For example, this could include alterations that result in the upregulation of *AKT3*, a condition which promotes tumor progression in *BRAF** melanomas (Cheung et al., 2008). If *BRAF* and *NRAS* mutations are similar in their transforming mechanism, then they should be associated with either the same specific aberrations or a similar random aberration profile (i.e., a copy number phenotype). To test these hypotheses, we surveyed a set of melanoma cell lines and tumors for both *BRAF* and *NRAS* sequence mutations and genome-wide DNA copy number alterations using array comparative genomic hybridization (aCGH). The direct comparison between the mutation-specific profiles of cell lines and tumors both validates a putative profile as well as defines regions where cell lines may contain in vitro-derived genetic aberrations.

MATERIALS AND METHODS

Melanomas

A panel of 52 unique melanoma cell lines were obtained from the lab of Mehnard Herlyn (Wistar Institute, University of Pennsylvania) and were grown in conditions similar to those described in Ji et al., (2007) (cell line details can be seen in Supporting Information Table S1). Briefly, lines were cultured in 5% CO₂ atmosphere, at 37°C and in DMEM medium supplemented with 10% fetal bovine serum and 100 U/ml penicillin. All reagents for cell culture were purchased from Invitrogen (Carlsbad, CA). Melanoma tumors were obtained from the University of Pennsylvania, the Karolinska Institute and Fox Chase Cancer Center under the approval of the Institutional Review Board (details in Supporting Information Table S2). Only specimens containing at least 50% tumor cells (as evaluated by light microscopy) were included in the final panel. Genomic DNA was isolated from frozen tumor or cultured cells by overnight digestion, phenol-chloroform extraction, and ethanol precipitation.

Mutation Detection

Using similar methods to those described in Davies et al., (2002), exons 11 and 15 of the *BRAF* locus and exon 2 of *NRAS* were screened for mutations. This involved direct sequencing of genomic DNA from PCR products using an ABI 3100 DNA Sequencer (Applied Biosystems, Foster City, CA). Ultimately, every cell line and tumor was classified as being *BRAF**, *NRAS**, or wild type for both loci.

Array CGH

Melanomas were assayed on a 1-Mb resolution BAC clone-based CGH array designed specifically for cancer analysis (Greshock et al., 2004). One microgram of tumor and reference DNA (pooled lymphocyte-derived DNA from 10 individuals) were labeled with Cy3 or Cy5 fluorescent dyes, respectively (Amersham, Piscataway, NJ) using the BioPrime random-primed labeling kit (Invitrogen, Carlsbad, CA). In parallel experiments, melanoma DNA and reference DNA were labeled with the opposite dye ("dye swap") to account for difference in dye incorporation. Labeled tumor and reference DNA were then combined and precipitated with human Cot-1 DNA to reduce nonspecific binding. DNA was then resuspended and hybridized to the array for 72 hr

at 37°C on a rotating platform. Images were scanned with an Axon 4500 microarray scanner (Axon Instruments, Union City, CA) and analyzed with the accompanying GenePix software. Data for a subset of the samples have been previously published (Zhang et al., 2006).

Data Analysis

All BAC clones were mapped to human genome build 34 (July 2003) using data provided by the UCSC genome browser site (<http://genome.ucsc.edu>) or by manual alignment. For each probe on every assay, a \log_2 copy number ratio was measured from raw data derived from the scanned image by dividing the test channel image intensity by that of the reference channel. Ratios of duplicate clones were averaged for all assays. As a means of quality control, only clones with at least 80% foreground pixel intensity 2 SDs greater than the mean background intensity were considered for analyses. Subsequently, every assay was normalized under the assumption that median copy number was diploid resulting in the median \log_2 ratio being zero. Data from each dye-swap were combined and evaluated by circular binary segmentation (CBS) to estimate copy number breakpoints (Olshen et al., 2004). Global copy number assignments for each sample were made by dividing the genome into 1 Mb intervals whose copy number status was determined by its associated CBS score. For subsequent χ^2 analysis, the copy number status of each region was categorized using ratio thresholds derived from previous studies of microarray signal response (Greshock et al., 2007a). These were ± 0.25 for gains ($< \sim 5$ copies) and monosomies, and > 0.55 for high level gains ($> \sim 5$ copies), and < -0.8 for homozygous deletions. Estimates of genome-wide aberration rates were made by simply calculating the proportion of segments gained or lost in a specific sample.

Statistical Analysis

To identify specific DNA alterations that could distinguish between genotypes (*BRAF*^{*}, *NRAS*^{*}, or *BRAF/NRAS*^{wt/wt}), a χ^2 test was applied to the occurrence of regional copy number changes under the null hypothesis that copy number alterations occur at equal frequencies between mutation groups. Genomic regions of 1 Mb served as units for comparison while copy number gains and losses were calculated separately under the

null hypothesis that aberrations would occur at equal frequency between mutation groups. The ability to distinguish one mutation group from another was measured by constructing support vector machine (SVM) models. A series of one-versus-one models were constructed using methods previously described (Brown et al., 2000) and trained with aCGH data from cell line models to compare mutation groups. All models were constructed using a linear kernel. The γ parameter and cost c were optimized through leave-one-out cross-validation using the cell line data, where those yielding the highest level of success were used. Genomic regions available for inclusion in the model were those occurring on chromosomes shown to have at least a subset of regions that were significantly different between mutation groups by the χ^2 test described earlier. The optimal regions of alteration were then used to classify all tumors.

RESULTS

General Mutation

All of the mutations at the *BRAF* locus were V600E. The overall frequency of this mutation in this sample set was 54.7% (52/95), although its occurrence was higher in cell lines (35/52; 67.3%) than in tumors (17/43; 39.5%) ($P = 0.006$). As expected, *NRAS* mutations were seen at lower frequencies than *BRAF* mutations (24/95; 25.4%), and were observed at approximately equal frequencies between cell lines (11/52; 21.2%) and tumors (13/43; 30.2%) ($P = 0.22$). No tissue or cell line was comutated for both *BRAF* and *NRAS*.

Genome-Wide CGH

Cell lines demonstrated uniformly higher rates of genome-wide chromosomal gain and loss than did tumors samples (t -test; $P = 0.0004$ and $P = 0.0248$, respectively) (Fig. 1A). Although there was no difference in genome-wide aberration rates between mutation groups, instability of several individual chromosomes emerged as being associated with the occurrence of a mutation (Table 1). Most notably, copy number gains of chromosome 7 were seen at higher rates in *BRAF*^{*} tumors and cell lines (Fig. 2B; $P = 0.0199$ and $P = 0.0172$ for tumors and cell lines, respectively), whereas losses of chromosome 4 were associated with *NRAS* mutants. A survey across the genome for subchromosomal copy number alterations in




Figure 1. Copy number instability as measured by the proportion of each sample subject to DNA copy number gains in *BRAF*⁺ tumors compared with *NRAS*⁺ and *BRAF/NRAS*^{wt/wt}. (A) Total aberrations across the entire genome are higher in cell lines when compared with primary tumors (t-test; *P* = 0.0004). (B) Aberrations on chro-

mosome 7 are more common in *BRAF*⁺ tissues when compared with all *BRAF*^{wt} tissues (*P* = 0.0199 and *P* = 0.0172 for tumors and cell lines, respectively). (C) Specific gains of 7q32.1-36.3, represented in each sample as the green regions along the vertical ideogram of chromosome 7, strongly associate with *BRAF*⁺ tissues.

TABLE I. Chromosomes Demonstrating Differential Aberration Rates in *BRAF*⁺ or *NRAS*⁺ Samples for Both Cell Lines and Tumors Include 4, 7, and 12

Chrom.	Mutation association	Aberration type	Tumors		Cell lines		<i>P</i> -value (tumors, cell lines)
			Mutant (n = 17)	Wild type (n = 26)	Mutant (n = 35)	Wild type (n = 17)	
4	<i>NRAS</i> ⁺	Loss	1.5 (3.9)	12.9 (22.8)	9.4 (28.3)	31.9 (37.1)	0.0120; 0.0359
12	<i>NRAS</i> ⁺	Gain	0.8 (1.9)	7.1 (10.0)	0.5 (1.1)	6.0 (10.0)	0.0027; 0.0011
7	<i>BRAF</i> ⁺	Gain	48.4 (35.3)	21.8 (34.2)	58.2 (37.9)	24.0 (38.0)	0.0199; 0.0172

Aberration rates were quantified by the proportion of the chromosome gained or lost. Standard deviations of these proportions appear in parentheses.

melanoma tumors and cell lines demonstrated distinct patterns of alterations that are associated with *BRAF* and *NRAS* mutation groups (Fig. 2).

When considering only tumor samples, mutations of the *BRAF* locus were most closely associated with the presence of copy number gains of the




Figure 2. Genomic frequency plot depicting the copy number alteration frequency of aberrations for (A) *BRAF*^{*}, (B) *NRAS*^{*}, and (C) *BRAF/NRAS*^{wt/wt} cell lines and tumors. Cell lines, gains (plotted in green) and losses (red) generally had higher alteration frequencies than did primary tumors (dark needles). (D) A χ^2 statistic for tumors (blue) and cell lines (yellow; overlap plotted in dark shade) identifies

regions differentiating mutation groups. Those *P*-values above the ideogram represent regions of gain, whereas those below represent regions of loss. The regions that demonstrate the best concordance between cell lines and tumors include gains of 7q32.1-36.3 (shaded green) and gain of 5p15.33-31 (shaded red).

regions surrounding this gene, including 7q32.1-36.3 (Fig. 1C). In tumors, the regions surrounding *BRAF* demonstrated copy number gains in 12/17 *BRAF*^{*} (71%), while only 4/26 wild types (15%) ($P = 0.0004$; Fisher's exact test) (Fig. 2A). Similarly, in cell lines, rates of *BRAF* locus gain were higher in *BRAF*^{*} (23/35; 66%) than wild types (3/17; 18%) ($P = 0.0012$; Fisher's exact test). Other copy number alterations associated with *BRAF* mutations are gains of 5p15.31 and 5p13.2 as well as the frequent chromosomal losses of 11q24.2-24.3 and 17q12-21.2 (top regions differentiating mutation groups can be seen in Table 2). Expectedly, the absence of a 7q32.1-36.3 gain was associated with *NRAS*^{*} tumors and *BRAF/NRAS*^{wt/wt} tissues. Additionally, gains of 5p15.31 and 5p13.2

as well as losses of 22p13 occurred more frequently in *NRAS*^{*} tissues when compared with *BRAF/NRAS*^{wt/wt}. Similarly, 5p15.31 gains more readily distinguished *BRAF*^{*} from *NRAS*^{*} tumors, as did losses of 16q21.1. Losses of 11q24.2-25 occurred more frequently in *NRAS*^{*} when compared with *BRAF*^{*} tumors.

SVM Modeling

A simple cell line-derived copy number alteration prediction model employing SVMs for *BRAF* mutation status prediction was internally cross-validated in cell lines with a success rate of 86% using a leave-one-out scheme. The consensus cell line-based model (loci noted in Table 2)

TABLE 2. Subchromosomal Loci that Best Differentiate *BRAF*^{*}, *NRAS*^{*}, and *BRAF/NRAS*^{wt/wt} Melanomas as Measured by χ^2 Analysis

	Region	Association
<i>BRAF</i> [*] vs. WT	7q32.1-36.3	Gain, <i>BRAF</i> [*]
	5p15.31	Gain, <i>BRAF</i> [*]
	5p13.2	Gain, <i>BRAF</i> [*]
	8q21.11	Gain, WT
	8q24.11	Gain, WT
	11q24.2-24.3	Loss, <i>BRAF</i> [*]
<i>NRAS</i> [*] vs. WT	17q12-21.2	Loss, <i>BRAF</i> [*]
	4p16.1-15.2	Loss, WT
	5p15.31	Gain, WT; Loss <i>NRAS</i> [*]
	5p13.2	Gain, WT; Loss <i>NRAS</i> [*]
	7q31.11-36.3	Gain, WT
	17q.12	Loss, WT
<i>BRAF</i> [*] vs. <i>NRAS</i> [*]	22p13	Loss, <i>NRAS</i> [*]
	5p15.31	Gain, <i>BRAF</i> [*]
	7q32.1-35	Gain, <i>BRAF</i> [*]
	11q24.2-25	Loss, <i>NRAS</i> [*]
	16q21.1-qter	Loss <i>BRAF</i> [*]

Many regions differentiating *BRAF*^{*} tumors from *BRAF/NRAS*^{wt/wt} also distinguish *BRAF*^{*} from *NRAS*^{*} tissues.

classified 75% of tumors correctly. Only two *BRAF*^{*} tumors ($n = 17$) were misclassified as wild types, whereas 17/26 *BRAF*^{wt} tumors were classified correctly, indicating a high sensitivity but reduced specificity. Based upon 1000 permutations, where mutations classes were randomly assigned, this model performed better than expected by chance given the permuted data (95% CI: 19.3–72.6%; $P < 0.05$). A similar model, constructed to predict *NRAS*^{*} cell lines from wild types, successfully distinguished 21/30 *NRAS* wild types, although only correctly identified 6/13 *NRAS* mutants ($P = 0.12$).

High-Level Amplifications

Although the occurrence of amplifications estimated to be >5 copies were relatively rare compared with all copy number gains, several recurring regions of amplification appeared to be common to both tumors and cell lines. The most common high-level amplification seen in the tumor population was that of 7q33 (~136-7 Mb), which was observed in 6/43 samples (Table 3). Similarly, 8/52 cell lines showed amplification of this region. This was in close proximity to the *BRAF* locus, although only in two case did it encompass the gene (all genes mapping to this and other regions appear in Table 3). Considering both tumors and cell lines, there was a significant tendency for this amplification to occur in *BRAF*^{*} samples. Other recurring high-level amplifications

occurred on 1p and 20q. Recurring homozygous losses were noted on 10p14 and 16q24.3 in both tumor and cell line groups. Additionally, homozygous losses of *CDKN2A* were noted in 21% (11/52) of cell lines but only observed in 2.3% (1/43) primary tumors.

DISCUSSION

Both *BRAF* and *NRAS* function on the same growth factor receptor tyrosine kinase pathway, and activating mutations of either causes melanomas to have an active mitogen-activated protein kinase (MAPK) cascade when compared with *BRAF/NRAS*^{wt/wt} cells (Shields et al., 2007). Moreover, this oncogenic convergence is supported by the ability of MEK inhibition to cause tumor regressions in either *BRAF* or *RAS* induced cancers (Ji et al., 2007). If somatic mutations of *BRAF* and *NRAS* transform melanoma cells via similar mechanisms, then the manifestation of cooperating aberrations, such as copy number aberrations, may be expected to be similar. These results indicate that *BRAF*^{*} melanomas harbor a distinct set of DNA copy number alterations from those found in *NRAS*^{*} and *BRAF/NRAS*^{wt/wt} tumors. This result suggests that although both *BRAF* and *NRAS* function along the same signaling pathway, the cooperating events required or the resultant copy number profile phenotype are distinct for different mutation groups.

This hypothesis is predicated on the observation that cell lines tend to be faithful genetic models of their parent histology both in terms of genome-wide copy number aberrations (Greshock et al., 2007b) and specific mutations (Jones et al., 2008). Previous studies of melanoma suggest this would be the case. Similar patterns of gain at 7q, and 20q as well as losses of 9p and 10q were characterized in both cell line models (Ji et al., 2007; Jonsson et al., 2007) and primary tumors (Curtin et al., 2005). Concordantly, these regions appeared as marquee alterations in both tumors and cell lines in this study. Focal amplifications also appear similar between this and previous studies. For example, the amplification of the metastatic melanoma candidate oncogene *NEDD9* (6p24.2) (Kim et al., 2006) was seen in 12% (5/43) of tumors. Recurring *E2F1* amplifications, thought to promote cell proliferation in melanomas (Roberts, 2006), was observed in both cell lines and tumors (3/52; 6% and 5/43; 12%, respectively).

TABLE 3. Multiple Genes Map to the Most Common High-Level Gains and Homozygous Deletions When Considering Both Cell Lines and Tumor Groups

Chrom.	Region (Mb)	Tumors			Cell lines			P-value	Genes		
		BRAF* (n = 17)	NRAS* (n = 13)	WT/WT (n = 13)	Total	BRAF* (n = 35)	NRAS* (n = 11)			WT/WT (n = 6)	Total
Amplifications											
7	136–137	5	1	0	6	7	1	0	8	0.031	CHRM2, PTN, DGKI, CREB3L2
20	59–60	3	0	1	4	5	2	0	7	0.2623	SCAPIN1, CDH26, SYCP2, PPP1R3D
20	32–33	3	1	1	5	3	1	0	4	0.4808	DNMT3B, MAPRE1, BP1I, SPAG4L, BASE, PLUNC, CDK5RAP1, SNTA1, EZFI
1	119–120	1	1	1	3	2	2	0	4	0.6071	WARS2, HAO2, HSD3B1, PHGDH, ADAM30, NOTCH2
Homozygous losses											
16	87–90	0	1	1	2	3	2	1	6	0.6298	JPH3, CA5A, SLC7A5, ZFPMI1, MVD, CYPA, ILI17C, APRT, GALNS, FANCA, CDK10, DPEP1, CPNE7, SPG7, TUBB4
10	6.0–9.0	1	3	0	4	7	0	1	8	0.5123	IL2RA, PRKCQ, PFKFB3, ITIH2, GATA3, ATP5CA

The only high-magnitude alteration that distinguished between mutation groups was gain of 7q33 (136.7 Mb).

We were able to identify a DNA copy number profile that is associated with activating *BRAF* mutations in melanoma cell lines and tumors, where a simple copy number alteration model derived from cell line data reliably predicted the *BRAF* mutation status of 75% of primary tumors. This is not surprising as *BRAF* mutations have also been found in benign nevi, suggesting that additional cooperating events may be necessary for full transformation (Pollock et al., 2003). Two outstanding predictive features of *BRAF** tumors are general instability of chromosome 7 and the specific copy number gains of 7q32.1-36.3 (the region encompassing the *BRAF* locus). This region also harbored the only high-level copy number amplification ($\sim >5$ copies) that was connected with a mutation group, an observation concordant with previous chromosomal CGH studies (Tanami et al., 2004). Also, Curtin et al. (2005) noted that sporadic melanomas of the skin (a subgroup with high rates of *BRAF* mutations) are subject to instability on 7q, although this specific association with *BRAF** tumors had been previously undocumented. These data are reminiscent of previous observations that activating mutations of epidermal growth factor receptor in lung cancer often occur within subchromosomal amplicons, (Bell et al., 2005). Transcript abundance for genes mapping to 7q is concordant with the increased copy number alterations seen in *BRAF** tumors where 15/18 differentially expressed transcripts ($P < 0.05$) on 7q were up-regulated in *BRAF** cell lines [data from Pavvey et al. (2004)]. Although this observation is consistent with fluorescence in situ hybridization studies noting differential allelic imbalance and distinct amplification of mutant alleles in the region adjacent to the *BRAF* locus in *BRAF** tumors (Willmore-Payne et al., 2006), its functional relevance remains unclear.

Although there was less consistency in DNA copy number alterations that were associated with *NRAS* mutations, losses of chromosome 4 and gains of chromosome 12 appeared strongly associated in both cell lines and tumors. Specific losses of 5p15.31 and 5p13.2 as well as losses of 22p13 also associate with *NRAS* mutations; however, we were unable to build a cell line-based predictive model for *NRAS* mutations that effectively characterized tumors. Under the hypothesis that associated DNA copy number changes are nonrandom (i.e., they have functional implications), there may be several reasons for this result: (a) the oncogenic insult conferred by

*NRAS** is sufficient on its own (such that additional aberrations would be random); (b) *NRAS** can cooperate with a multitude of different genetic aberrations where this tumor sample size being underpowered to detect such a profile (i.e., Type II error); (c) more common cooperating genetic lesions are point mutations that would be missed by copy number analyses and (d) *NRAS** occur as late in the oncogenic cascade on a background of different genetic predispositions (this explanation, however, would be contrary to numerous preclinical models whereby *Ras** is sufficient for transformation). Finally, these results are consistent with the observation by Lin et al. (2008) that *NRAS** cell lines inconsistently clustered based on key copy number alterations.

Considering the clinical and pathological variation seen in melanomas, it is not surprising that they represent a genetically heterogeneous group of cancers. Recent data have contributed to much better understanding of the molecular classification of these tumors (Fecher et al., 2007).

In both crossvalidation and tumor prediction, a proportion of *BRAF* wild-type melanomas appeared to present a DNA copy number profile similar to that of mutant tumors. This observation has several possible implications. First, this could infer that these associated alterations could be cooperating with other yet undescribed activators of RAF/MEK/ERK signaling. Second, this could also imply that some of the alterations compose a copy number phenotype manifested in *BRAF** melanomas that could be recapitulated in a subset of *BRAF* wild-type melanomas. This may prove to be the case as the functional relevance of most DNA alterations associating with *BRAF** and *NRAS** tumors remains unclear. As a potential analogy, patterns of aneuploidy have been extensively associated with *TP53** tumors (summarized in Tomasini et al. (2008), a condition that may manifest itself uniquely in different histologies.

This study suggests that *BRAF** melanomas appear to have a more well-defined oncogenic profile than *NRAS** tumors. The more homogeneous series of genetic aberrations that correlate with *BRAF** melanomas may have several therapeutic implications. First, this may provide insight into specific therapeutic targets that may be relevant only in the context of an activated *BRAF*. For example, recently described synthetic lethality of oncrasin-1 treatment with those cells harboring *KRAS* mutations suggests cooperating loci that may be required for mutant tumor

survival (Guo et al., 2008). Second, as a novel class of compounds targeting the RAF/MEK/ERK signaling pathway have proven preferentially effective for inhibiting proliferation in *BRAF** cells, a more complete understanding of the genetic alterations that cooccur with mutations of *BRAF** tumors could identify therapies that may prove synergistic with inhibitors of this pathway. This class of compounds includes those targeting Raf kinases directly, such as sorafenib and AZ628 (McDermott et al., 2007) as well as inhibitors targeting MAPKs such as PD184352/CI-1040 (Solit et al., 2006). In this study, the cooccurring amplification of the de novo methylation regulator *DNMT3B* (20q11.21) in *BRAF** tumors suggests synergy between existing cancer therapies such as 5-aza-2'-deoxycytidine and those targeting RAF/MEK/ERK signaling. Finally, in the context of melanoma, associated DNA amplifications may provide novel targets for preventing *BRAF** nevi from progression.

REFERENCES

- Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. 2005. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. *J Clin Oncol* 23:8081–8092.
- Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, Borresen-Dale AL, Pollack JR. 2006. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. *Genes Chromosomes Cancer* 45:1033–1040.
- Brown MP, Grundy WN, Lin D, Cristianini N, Sugnet CW, Furey TS, Ares M, Jr. Haussler D. 2000. Knowledge-based analysis of microarray gene expression data by using support vector machines. *Proc Natl Acad Sci USA* 97:262–267.
- Cheung M, Sharma A, Madhunapantula SV, Robertson GP. 2008. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. *Cancer Res* 68:3429–3439.
- Chudnovsky Y, Khavari PA, Adams AE. 2005. Melanoma genetics and the development of rational therapeutics. *J Clin Invest* 115:813–824.
- Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutznier H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC. 2005. Distinct sets of genetic alterations in melanoma. *N Engl J Med* 353:2135–2147.
- Curtin JA, Busam K, Pinkel D, Bastian BC. 2006. Somatic activation of *KIT* in distinct subtypes of melanoma. *J Clin Oncol* 24:4340–4346.
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. 2002. Mutations of the *BRAF* gene in human cancer. *Nature* 417:949–954.
- Eskandarpour M, Kiaii S, Zhu C, Castro J, Sakko AJ, Hansson J. 2005. Suppression of oncogenic *NRAS* by RNA interference induces apoptosis of human melanoma cells. *Int J Cancer* 115:65–73.
- Fecher LA, Cummings SD, Keefe MJ, Alani RM. 2007. Toward a molecular classification of melanoma. *J Clin Oncol* 25:1606–1620.
- Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN, McLennan J, Ziegler J, Chin K, Devries S, Feiler H, Gray JW, Waldman F, Pinkel D, Albertson DG. 2006. Breast tumor copy number aberration phenotypes and genomic instability. *BMC Cancer* 6:96.
- Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ, Nikiforov YE. 2005. Molecular classification of papillary thyroid carcinoma: Distinct *BRAF*, *RAS*, and *RET/PTC* mutation-specific gene expression profiles discovered by DNA microarray analysis. *Oncogene* 24:6646–6656.
- Greshock J, Naylor TL, Margolin A, Diskin S, Cleaver SH, Futreal PA, deJong PJ, Zhao S, Liebman M, Weber BL. 2004. 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. *Genome Res* 14:179–187.
- Greshock J, Feng B, Nogueira C, Ivanova E, Perna I, Nathanson K, Protopopov A, Weber BL, Chin L. 2007a. A comparison of DNA copy number profiling platforms. *Cancer Res* 67:10173–10180.
- Greshock J, Nathanson K, Martin AM, Zhang L, Coukos G, Weber BL, Zaks TZ. 2007b. Cancer cell lines as genetic models of their parent histology: Analyses based on array comparative genomic hybridization. *Cancer Res* 67:3594–3600.
- Guo W, Wu S, Liu J, Fang B. 2008. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. *Cancer Res* 68:7403–7408.
- Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. 2003. Suppression of *BRAF*(V599E) in human melanoma abrogates transformation. *Cancer Res* 63:5198–5202.
- Hoefflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM, Murray LJ, Davis DP, Seshagiri S. 2006. Oncogenic *BRAF* is required for tumor growth and maintenance in melanoma models. *Cancer Res* 66:999–1006.
- Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghoul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chiriac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, Janne PA, Johnson BE, Chin L, Wong KK. 2007. Mutations in *BRAF* and *KRAS* converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. *Cancer Res* 67:4933–4939.
- Jones S, Chen WD, Parmigiani G, Diehl F, Beerwinkler N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD. 2008. Comparative lesion sequencing provides insights into tumor evolution. *Proc Natl Acad Sci USA* 105:4283–4288.
- Jonsson G, Dahl C, Staaf J, Sandberg T, Bendahl PO, Ringner M, Guldberg P, Borg A. 2007. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. *Oncogene* 26:4738–4748.
- Kabbarah O, Chin L. 2005. Revealing the genomic heterogeneity of melanoma. *Cancer Cell* 8:439–441.
- Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, Brennan C, Hahn WC, Cordon-Cardo C, Wagner SN, Flotte TJ, Duncan LM, Granter SR, Chin L. 2006. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. *Cell* 125:1269–1281.
- Lin WM, Baker AC, Beroukhir R, Winckler W, Feng W, Marmorin JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA. 2008. Modeling genomic diversity and tumor dependency in malignant melanoma. *Cancer Res* 68:664–673.
- Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D, Bastian BC. 2003. Determinants of *BRAF* mutations in primary melanomas. *J Natl Cancer Inst* 95:1878–1890.
- McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulluks LE, Iafra AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J. 2007. Identification of

- genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. *Proc Natl Acad Sci USA* 104:19936–19941.
- Neben K, Schnittger S, Brors B, Tews B, Kokocinski F, Haferlach T, Muller J, Hahn M, Hiddemann W, Eils R, Lichter P, Schoch C. 2005. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype. *Oncogene* 24:1580–1588.
- Olshen AB, Venkatraman ES, Lucito R, Wigler M. 2004. Circular binary segmentation for the analysis of array-based DNA copy number data. *Biostatistics* 5:557–572.
- Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. 2003. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. *Clin Cancer Res* 9:6483–6488.
- Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, Walker GJ, Boyle GM, Harper U, Cozzi SJ, Hansen K, Yudit L, Schmidt C, Hersey P, Ellem KA, O'Rourke MG, Parsons PG, Meltzer P, Ringner M, Hayward NK. 2004. Microarray expression profiling in melanoma reveals a BRAF mutation signature. *Oncogene* 23:4060–4067.
- Pollock PM, Harper UL, Hansen KS, Yudit LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS. 2003. High frequency of BRAF mutations in nevi. *Nat Genet* 33:19–20.
- Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, Redman B, Thomas NE, Gruber SB. 2006. BRAF and NRAS mutations in melanoma and melanocytic nevi. *Melanoma Res* 16:267–273.
- Roberts JD. 2006. E2F1 amplification and genetic heterogeneity in melanoma. *Cancer Biol Ther* 5:691–692.
- Shields JM, Thomas NE, Cregger M, Berger AJ, Leslie M, Torrice C, Hao H, Penland S, Arbiser J, Scott G, Zhou T, Bar-Eli M, Bear JE, Der CJ, Kaufmann WK, Rimm DL, Sharpless NE. 2007. Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. *Cancer Res* 67:1502–1512.
- Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. 2006. BRAF mutation predicts sensitivity to MEK inhibition. *Nature* 439:358–362.
- Tanami H, Imoto I, Hirasawa A, Yuki Y, Sonoda I, Inoue J, Yasui K, Misawa-Furihata A, Kawakami Y, Inazawa J. 2004. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. *Oncogene* 23:8796–8804.
- Tomasini R, Mak TW, Melino G. 2008. The impact of p53 and p73 on aneuploidy and cancer. *Trends Cell Biol* 18:244–252.
- Uribe P, Wistuba II, Gonzalez S. 2003. BRAF mutation: A frequent event in benign, atypical, and malignant melanocytic lesions of the skin. *Am J Dermatopathol* 25:365–370.
- Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ. 2006. BRAF and c-kit gene copy number in mutation-positive malignant melanoma. *Hum Pathol* 37:520–527.
- Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, Yao G, Medina A, O'Brien-Jenkins A, Katsaros D, Hatzigeorgiou A, Gimotty PA, Weber BL, Coukos G. 2006. microRNAs exhibit high frequency genomic alterations in human cancer. *Proc Natl Acad Sci USA* 103:9136–9141.